Sign In

Drug-induced Liver Injury in Children: Causes, Criteria and Complications

Date/Time 

  • Friday, October 20, 2017, 4:15-6:15 pm

Program Chairs  

  • Robert H. Squires, MD, FAASLD
  • Emily R. Perito, MD

Continuing Education Information

  • CME –  1.75 AMA PRA Category 1 Credits™ 

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify common causes of drug-induced liver injury in children and the associated mechanisms of injury.
  • Diagnose drug-induced liver injury in children.
  • Manage and report suspected DILI cases in children.

Session Description/Needs Statement

As the number and type of drugs used to treat pediatric illnesses proliferate, and the push to make new drugs available for children gains speed, understanding how to recognize drug-induced liver injury is increasingly important for pediatric liver providers. This program will focus on challenges and opportunities associated with the diagnosis and management of DILI that are unique to the pediatric population. Clinical presentations include surreptitious elevation of serum aminotransferase levels, acute liver injury with or without acute liver failure and chronic liver disease.

Program

  • Introduction/Welcome
  • 4:15-4:35 pm
    Causes of and Criteria For Drug-Induced Liver Injury in Children: Lessons From the Drug-Induced Liver Injury Network (DILIN) Prospective Study
    Jean P. Molleston, MD
  • 4:35-4:55 pm
    Are We Under-diagnosing DILI in Hospitalized Children?
    Ryan T. Fischer, MD
  • 4:55-5:05 pm
    Break
  • 5:05-5:25 pm
    Hepatotoxicity in the Treatment of Inflammatory Bowel Disease
    Binita M. Kamath, MBBChir
  • 5:25-5:45 pm
    Antibiotic-associated DILI
    Eve A. Roberts, MD, PhD, FAASLD
  • 5:45-6:05 pm
    Management and Reporting of Suspected DILI in Children
    Maclovio J. Lopez, MD, PhD
  • 6:05-6:15 pm
    Panel Discussion/Q&A